Evoke Pharma sees FY25 net product sales of approx $16M

Evoke is confirming its full-year 2025 net product sales guidance of approximately $16 million, representing up to a 60% increase over 2024. This guidance reflects Evoke’s current business outlook, including recent trends in prescription growth and refill rates, expanded pharmacy access, and the continued adoption of GIMOTI. The estimate also incorporates assumptions around payer reimbursements and conversion rates, as well as external factors that remain outside of the company’s control, including macroeconomic conditions, geopolitical volatility, supply chain constraints, and inflationary pressures.